Charles River Laboratories (CRL) Tops Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $273.00 -1.92%
Revenue Growth %: -4.3%
Financial Fact:
Income from continuing operations, net of tax: 37.69M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Income from continuing operations, net of tax: 37.69M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.75, $0.03 better than the analyst estimate of $2.72. Revenue for the quarter came in at $913.9 million versus the consensus estimate of $910.1 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $11.50-$11.75, versus the consensus of $11.64.
- Revenue growth, reported 13.5% – 15.5%
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- Copart (CPRT) Misses Q4 EPS by 4c
- IBEX Limited (IBEX) Tops Q4 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
